Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,261 matching trials from the live ClinicalTrials.gov search.
Conditions
Anxiety, PTSD, ADHD, Depression Disorders, Post-traumatic Stress, Substance Use, Executive Function, Sleep Disturbance
Interventions
AIP-Informed Integrative Psychotherapy, Transcutaneous Auricular Vagus Nerve Stimulation, Regulated Breathing and Autonomic Regulation, Audiovisual Entrainment, Vibroacoustic Stimulation, Breathwork-Based Auditory Driving Entropy Module (BADEM), Transcranial Electrical Stimulation
Behavioral · Device
Lead sponsor
Tactical Mind Research Coalition, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-433

NCT07584434
Conditions
Narcolepsy Type 1 (NT1)
Interventions
VX-433, Placebo, Midazolam, Bupropion
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more
Conditions
Solid Tumor
Interventions
CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 15 more
Conditions
Relapsing Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more
Conditions
Multiple Myeloma, Advanced Solid Tumors
Interventions
Ixazomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Atlanta, Georgia • Peoria, Illinois • Fairway, Kansas + 7 more
Conditions
Platinum-resistant Ovarian Cancer
Interventions
NP-G2-044, PLD
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Shreveport, Louisiana • Albuquerque, New Mexico + 3 more
Conditions
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
Interventions
NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2043
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 14 more
Conditions
Asthma
Interventions
SM17, Placebo
Biological · Other
Lead sponsor
SinoMab BioScience Ltd
Industry
Eligibility
19 Years to 55 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
Interventions
BAL0891, Tislelizumab, Paclitaxel
Drug · Combination Product
Lead sponsor
SillaJen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more
Conditions
Depressive Symptoms
Interventions
Group-based therapy
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
18 Years to 28 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Eugene, Oregon
Conditions
Non-small Cell Lung Cancer
Interventions
ISIS EIF4E Rx, Paclitaxel, Carboplatin
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Hot Springs, Arkansas + 6 more
Completed Not applicable Interventional Results available

Implementing Evidence Based Treatment of Hypertension

NCT00265538
Conditions
Hypertension
Interventions
Patient educational letter to engage provider in hypertension rx discussion, Financial incentive (Arms B and C) and health educator phone call (Arm C)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Iowa City, Iowa • Minneapolis, Minnesota
Conditions
Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Waldenstrom Macroglobulinemia, Primary Mediastinal B-cell Lymphoma
Interventions
ADCT-402
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • St Louis, Missouri + 4 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lifestyle Education for Activity and Nutrition for a Leaner You

NCT00957008
Conditions
Body Weight Changes, Overweight
Interventions
Group weight loss program, Group weight loss program plus use of the Senseware Armband, Use of the senseware armband alone program
Behavioral · Other · Device
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, South Carolina
Conditions
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
Interventions
OP-1250
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more
Conditions
Advanced Solid Tumor
Interventions
Valemetostat tosylate, T-DXd, Dato-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Irvine, California • San Diego, California • Plantation, Florida + 13 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating Raised Intracranial Pressure Using MR Elastography

NCT03096743
Conditions
Idiopathic Intracranial Hypertension
Interventions
MR elastography, MRI structural brain imaging, Lumbar puncture, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound
Diagnostic Test · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

NCT05486208
Conditions
Healthy, Dermatitis, Atopic
Interventions
LY3844583, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Conditions
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
Interventions
INCB106385, INCMGA00012
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
West Hollywood, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
U3-1287, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3074828 in Healthy Participants

NCT03456713
Conditions
Healthy
Interventions
LY3074828
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 1 Interventional Results available

A Phase 1 Study of LY2787106 in Cancer and Anemia

NCT01340976
Conditions
Anemia
Interventions
LY2787106, Iron Supplementation
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
La Jolla, California • Santa Monica, California • Indianapolis, Indiana + 6 more
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Use of Methylone in the Treatment of PTSD

NCT05741710
Conditions
Post Traumatic Stress Disorder
Interventions
Methylone, Placebo
Drug
Lead sponsor
Transcend Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Denver, Colorado • Jacksonville, Florida • Maitland, Florida + 5 more